The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas-Reference-Cited by-同舟云学术

The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas

Published:2011-08-26 Issue:1 Volume:25 Page:131-139
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Lee Dakeun,Do In-Gu,Choi Kyusam,Sung Chang Ohk,Jang Kee-Taek,Choi Dongwook,Heo Jin Seok,Choi Seoung Ho,Kim Jongmin,Park Jin Young,Cha Hyung Jin,Joh Jae-Won,Choi Kwan Yong,Kim Dae Shick

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2011133.pdf

Reference46 articles.

1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473.

2. Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357.

3. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 2006;94:1751–1758.

4. Jarnagin WR, Shoup M . Surgical management of cholangiocarcinoma. Semin Liver Dis 2004;24:189–199.

5. Altomare DA, Testa JR . Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455–7464.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice;Journal of Hepatology;2024-07

2. Bortezomib in previously treated phosphatase and tension homology‐deficient patients with advanced intrahepatic cholangiocarcinoma: An open‐label, prospective and single‐centre phase II trial;Clinical and Translational Medicine;2024-04-30

3. The interplay of signaling pathways with miRNAs in cholangiocarcinoma pathogenicity and targeted therapy;Pathology - Research and Practice;2023-05

4. Bortezomib in PTEN-deficient patients with advanced intrahepatic cholangiocarcinoma: an open-label, prospective, phase II trial;2023-03-17

5. Bortezomib in PTEN-deficient patients with advanced intrahepatic cholangiocarcinoma: an open-label, prospective, phase II trial;2023-03-13